Dermatitis, Atopic Clinical Trial
Official title:
Interdependent Quality of Life in Parent-Child Dyads Adjusting to Eczema: Effects of a Randomized Controlled Trial of the Integrative Body-Mind-Spirit Group Intervention
This randomized controlled trial aims to examine the efficacy of two integrative body-mind-spirit interventions, compared to a health education active control, in promoting adaptive emotional regulation and quality of life of children with eczema and their parent caregivers in Hong Kong. It also aims to examine the interdependent associations between children and their parent caregivers' baseline primary outcomes and the post-intervention changes in primary outcomes.
Status | Recruiting |
Enrollment | 192 |
Est. completion date | December 31, 2023 |
Est. primary completion date | October 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Years to 100 Years |
Eligibility | Inclusion Criteria (Children): - age 6-12 - are diagnosed with atopic dermatitis as assessed by the doctors (ICD-10 Revision codes L20-L30) - are able to communicate in Cantonese - give their consent to participate in this RCT - obtain parental consent to participate in this RCT Inclusion Criteria (Parent caregivers): - are the primary caregivers of the child participants - are able to communicate in Cantonese - give their consent to participate in this RCT Exclusion Criteria (Children): - are diagnosed with Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Exclusion Criteria (Parent caregivers): - exhibit a history of family abuse - present with clinically significant psychiatric morbidity such as psychosis |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Department of Social Work and Social Administration | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Satisfaction with Treatment Program Scale | It has 5 items. It measures parent caregivers' satisfaction with the intervention. Scores range from 5 to 25, where a higher score represents lower satisfaction. | Post-intervention: 6 weeks after intervention initiation | |
Other | Demographics | Single items will be used to measure children's demographics (age, gender, and education level), as well as their parent caregivers' demographics (age, gender, education level, marital status, employment status, household income, type of housing, number of children). | Baseline | |
Other | Childhood eczema onset age | One single item will be used to measure the onset age of childhood eczema. | Baseline | |
Other | Current treatment for childhood eczema | Seven items will be used to measure the types of eczema treatments the children are receiving. | Baseline | |
Other | Cross-condition contamination check | Two items will be used to control for the confounding effect of unexpected exposure to I-BMS intervention materials during the trial on primary outcomes. Only participants in the health education active control group (arm 3) will complete it. | Post-intervention: 6 weeks after intervention initiation | |
Other | Presence of other clinical co-morbidities | Two items will be used to gather information about the presence of other clinical co-morbidities (e.g., allergy) among the children | Baseline | |
Primary | Changes over the measurement points in the Family Dermatology Life Quality Index | It has 10 items. It measures how much a child with atopic dermatitis affects the quality of life of their parent caregivers. Scores range from 0 to 30, where a high score represents a greater effect on the life of the parent caregiver. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Primary | Changes over the measurement points in the Children's Dermatology Life Quality Index | It has 10 items. It measures the impact of atopic dermatitis on the lives of children. Scores range from 0 to 30, where a higher score represents a greater impact on the child's life. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Primary | Changes over the measurement points in the Cognitive Emotion Regulation Questionnaire - Short Version | It has 18 items. It measures the specific cognitive emotion regulation strategies parent caregivers have used when caring for their children. It has nine subscales, namely, self-blame, other-blame, rumination, catastrophizing, putting into perspective, positive refocusing, positive appraisal, acceptance and planning. Subscale scores range from 2 to 10, where a higher score represents more usage of a specific cognitive emotion strategy. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Primary | Changes over the measurement points in the Short Version of the Cognitive Emotion Regulation Questionnaire for Spanish Kids | It has 18 items. It measures the specific cognitive emotion regulation strategies children have used to cope with their illness experience. It has nine subscales, namely, self-blame, other-blame, rumination, catastrophizing, putting into perspective, positive refocusing, positive appraisal, acceptance and planning. Subscale scores range from 2 to 10, where a higher score represents more usage of a specific cognitive emotion strategy. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Secondary | Changes over the measurement points in the Hospital Anxiety and Depression Scale | It has 14 items. It measures parent caregivers' emotional states of depression and anxiety. It has two subscales, namely, depression and anxiety. Subscale scores range from 0 to 21, where a higher score represents a higher level of depression or anxiety. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Secondary | Changes over the measurement points in the Revised Child Anxiety and Depression Scale - Short Version | It has 25 items. It measures children's emotional states of depression and anxiety. The depression subscale has 10 items, its scores range from 0 to 30, where a higher score represents a higher level of depression. The anxiety subscale has 15 items, its scores range from 0 to 45, where a higher score represents a higher level of anxiety. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Secondary | Changes over the measurement points in the Perceived Stress Scale for Children | It has 14 items. It measures children's emotional states of stress. One item is for illustration purposes and is not scored. Scores range from 0 to 39, where a higher score represents a higher level of stress. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Secondary | Changes over the measurement points in the Perceived Stress Scale | It has 10 items. It measures parent caregivers' emotional states of stress. Scores range from 0 to 40, where a higher score represents a higher level of stress. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Secondary | Changes over the measurement points in the Parent-Child Relationship Questionnaire - Personal Relationship Subscale (Parent Form) | It has 10 items. It measures parent caregivers' perception of their relationship quality with their children. Scores range from 10 to 50, where a higher score represents a better parent-child relationship. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Secondary | Changes over the measurement points in the Parent-Child Relationship Questionnaire - Personal Relationship Subscale (Child Form) | It has 10 items. It measures children's perception of their relationship quality with their parent caregivers. Scores range from 10 to 50, where a higher score represents a better parent-child relationship. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up | |
Secondary | Patient-Oriented Eczema Measure for Child (Parent Form) | It has 7 items. It measures parent caregivers' perception of their children's eczema severity. Scores range from 0 to 28, where a higher score represents more severe eczema. | Baseline, post-intervention: 6 weeks after intervention initiation, 6-week follow up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Terminated |
NCT04086121 -
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
|
Phase 2 | |
Recruiting |
NCT04011215 -
Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)
|
N/A | |
Completed |
NCT04635072 -
Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis
|
Early Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT01945086 -
A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT00541255 -
A Long-Term Examination of Asthma From Childhood Through Adolescence
|
||
Terminated |
NCT04990440 -
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02900131 -
Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients
|
Phase 2 | |
Completed |
NCT03568136 -
Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT03672383 -
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)
|
N/A | |
Completed |
NCT03634345 -
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
|
Phase 1 | |
Enrolling by invitation |
NCT04761978 -
Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
|
||
Completed |
NCT03663673 -
Effect of Different Skin Creams on TEWL
|
Phase 1 | |
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Completed |
NCT02637206 -
Skin Irritation Study of GSK2894512 Cream
|
Phase 1 | |
Completed |
NCT05544591 -
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT05094700 -
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
|
N/A |